Evaluation of out-of-pocket costs and treatment intensification with an SGLT2 inhibitor or GLP-1 RA in patients with type 2 diabetes and cardiovascular disease

J Luo, R Feldman, KC Kim, S Rothenberger… - JAMA Network …, 2023 - jamanetwork.com
Importance The latest guidelines continue to recommend sodium-glucose cotransporter 2
(SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients …

Pharmaceutical purchasing: a review of the landscape and implications for antidotal therapies

A Troger, MM Burns - Journal of Medical Toxicology, 2023 - Springer
The management of the poisoned patient often requires the utilization of uncommonly used
pharmaceutical interventions. These interventions can be associated with significant costs to …

[HTML][HTML] Simulated Medicare drug price negotiation under the Inflation Reduction Act of 2022

BN Rome, S Nagar, AC Egilman, J Wang… - JAMA Health …, 2023 - jamanetwork.com
Importance The Inflation Reduction Act of 2022 gives Medicare the authority to negotiate
prices for certain prescription drugs. Which drugs will be selected and how prices will be …

Rape-related pregnancies in the 14 US states with total abortion bans

SL Dickman, K White, DU Himmelstein… - JAMA internal …, 2024 - jamanetwork.com
Methods| Because to our knowledge no recent reliable statelevel data on completed vaginal
rapes (forced and/or drug/alcohol–facilitated vaginal penetration) are available, we …

Drugs likely subject to Medicare negotiation, 2026-2028

S Dickson, I Hernandez - Journal of Managed Care & Specialty Pharmacy, 2023 - jmcp.org
BACKGROUND: After the passage of the Inflation Reduction Act, Medicare will be able to
negotiate drug prices starting in 2026. The Congressional Budget Office has estimated the …

Stakeholder Perspectives of the Inflation Reduction Act's (2022) impact on prescription drugs: a narrative review

C Lieneck, M McLauchlan, V Adachi, R Billings - Pharmacy, 2023 - mdpi.com
In this review, we examine the impact of the Inflation Reduction Act (IRA) of 2022 on
pharmaceutical drugs in the United States, drawing on a diverse range of sources to …

Use of efficiency frontiers to align prices and clinical benefits of biologic therapies for plaque psoriasis

AC Egilman, AS Kesselheim, J Avorn… - JAMA …, 2024 - jamanetwork.com
Importance The US lacks a systematic approach for aligning drug prices with clinical benefit,
and traditional cost-effectiveness analysis (CEA) faces political obstacles. The efficiency …

The cancer premium–explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and …

M Serra-Burriel, G Perényi, Y Laube, AP Mitchell… - …, 2023 - thelancet.com
Background High treatment prices of new cancer drugs are a global public health challenge
to patients and healthcare systems. Policymakers in the US and Europe are debating …

Inflation Reduction Act and US drug pricing

A Sarpatwari - bmj, 2022 - bmj.com
The Inflation Reduction Act, which President Biden signed into US law on 16 August 2022,
contains bold measures to tackle climate change and reduce prescription drug costs. 1 The …

Medication cost concerns and disparities in patient-reported outcomes among a multiethnic cohort of patients with systemic lupus erythematosus

A Aguirre, K DeQuattro, S Shiboski, P Katz… - The Journal of …, 2023 - jrheum.org
Objective Concerns about the affordability of medications are common in systemic lupus
erythematosus (SLE), but the relationship between medication cost concerns and health …